{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:26:36Z","timestamp":1789014396632,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.clml.2018.02.013","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T13:30:11Z","timestamp":1519651811000},"page":"361-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"18","author":[{"given":"Reib\u00e1n-Espinoza","family":"Esteban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bourlon","family":"Christianne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aguayo","family":"Alvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Demichelis-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.02.013_bib1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/01.cco.0000245317.82391.1b","article-title":"The changing scene of adult acute lymphoblastic leukemia","volume":"18","author":"Vitale","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2018.02.013_bib2","author":"National Cancer Institute"},{"key":"10.1016\/j.clml.2018.02.013_bib3","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2018.02.013_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia","volume":"26","author":"Dieter","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2018.02.013_bib5","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE Project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.013_bib6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children\u2019s Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.013_bib7","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.013_bib8","first-page":"167","article-title":"Frecuencia de leucemias agudas en un hospital de referencia","volume":"50","author":"Gonz\u00e1lez-Salas","year":"2012","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"10.1016\/j.clml.2018.02.013_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.28531","article-title":"Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia","volume":"120","author":"Lim","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.013_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1471-2407-11-355","article-title":"Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology","volume":"11","author":"Perez-Saldivar","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2018.02.013_bib11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.013_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22 calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.02.013_bib13","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.02.013_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/asheducation-2011.1.243","article-title":"Novel antibody-based therapies for acute lymphoblastic leukemia","volume":"2011","author":"Hoelzer","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2018.02.013_bib15","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.013_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.013_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1179\/102453312X13221316477741","article-title":"CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value","volume":"17","author":"Solano-Genesta","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2018.02.013_bib18","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling","volume":"283","author":"Walshe","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2018.02.013_bib19","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.013_bib20","first-page":"1","volume":"6","author":"Prica","year":"2015","journal-title":"J\u00a0Cancer Ther"},{"key":"10.1016\/j.clml.2018.02.013_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia\/lymphoma","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.013_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.013_bib23","article-title":"Immunochemotherapy with rituximab in adult CD20 B-precursor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT","volume":"94","author":"Hoelzer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.013_bib24","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome\u2013negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.013_bib25","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.02.013_bib26","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.clml.2018.02.013_bib27","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.013_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/leu.2010.312","article-title":"Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet work package 10","volume":"25","author":"B\u00e9n\u00e9","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.013_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2018.02.013_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/sim.4780070309","article-title":"Multinomial regression models based on continuation ratios","volume":"7","author":"Cox","year":"1988","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2018.02.013_bib31","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3324\/haematol.2010.023457","article-title":"Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). L-asparaginase for adult CD20 positive B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.013_bib32","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3324\/haematol.2009.021089","article-title":"Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Chang","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.013_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.leu.2403559","article-title":"Drug induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection","volume":"19","author":"Gaipa","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.013_bib34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1515\/folmed-2016-0004","article-title":"Immunophenotypic modulation of the blast cells in childhood acute lymphoblastic leukemia: minimal residual disease detection","volume":"58","author":"Burnusuzov","year":"2016","journal-title":"Folia Med (Plovdiv)"},{"key":"10.1016\/j.clml.2018.02.013_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11899-011-0093-y","article-title":"Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"6","author":"Mathisen","year":"2011","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018301423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018301423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:53Z","timestamp":1761870593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018301423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S2152265018301423"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}